{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:31:24Z","timestamp":1782405084740,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.wneu.2020.09.082","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T11:39:24Z","timestamp":1600429164000},"page":"e813-e823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-6961","authenticated-orcid":false,"given":"Sarah A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-896X","authenticated-orcid":false,"given":"Malcolm D.","family":"Mattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2020.09.082_bib1","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib2","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2020.09.082_bib3","series-title":"Brain metastases in non-small cell lung cancer","author":"West","year":"2020"},{"key":"10.1016\/j.wneu.2020.09.082_bib4","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.wneu.2020.09.082_bib5","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2020.09.082_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2015.1145","article-title":"Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial","volume":"1","author":"Aoyama","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2020.09.082_bib9","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","article-title":"Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer","volume":"129","author":"Crin\u00f2","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2020.09.082_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.11.015","article-title":"Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data","volume":"126","author":"Dudnik","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2020.09.082_bib13","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib14","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"issue":"1S","key":"10.1016\/j.wneu.2020.09.082_bib15","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ijrobp.2019.06.453","article-title":"Final results of a phase II prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC)","volume":"105","author":"Campbell","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2020.09.082_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2020.09.082_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.wneu.2020.09.082_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/PAI.0000000000000408","article-title":"Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small cell lung cancer","volume":"24","author":"Roach","year":"2016","journal-title":"Appl Immunoihstochem Mol Morphol"},{"key":"10.1016\/j.wneu.2020.09.082_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non\u2013small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","article-title":"Prognostic value of the lung immune prognostic index for patients treated for metastatic non\u2013small cell lung cancer","volume":"5","author":"Kazandjian","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2020.09.082_bib22","first-page":"402","article-title":"Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries","volume":"6","author":"Lanier","year":"2019","journal-title":"Neurooncology Pract"},{"key":"10.1016\/j.wneu.2020.09.082_bib23","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.wneu.2020.09.082_bib26","article-title":"Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (nsclc) treated with pembrolizumab","volume":"36","author":"Goldberg","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2020.09.082_bib29","first-page":"477","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Natur Rev"},{"key":"10.1016\/j.wneu.2020.09.082_bib30","first-page":"1397","article-title":"Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects","volume":"129","author":"Diao","year":"2018","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2020.09.082_bib31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib32","first-page":"17","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2020.09.082_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases","volume":"125","author":"Kohutek","year":"2015","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fonc.2020.00012","article-title":"Tyrosine kinase inhibitor resistance increased the risk of cerebral radiation necrosis after stereotactic radiosurgery in brain metastases of non-small-cell lung cancer: a multi-institutional retrospective case-control study","volume":"10","author":"Zhuang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-017-2442-8","article-title":"The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies","volume":"133","author":"Kim","year":"2017","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib36","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"26","author":"Reungwetwattana","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib37","first-page":"1649","article-title":"Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma","volume":"33","author":"Hirata","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.wneu.2020.09.082_bib38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor-na\u00efve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib39","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib40","doi-asserted-by":"crossref","first-page":"5873-5882","DOI":"10.1158\/1078-0432.CCR-10-1588","article-title":"Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib","volume":"16","author":"Heon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2020.09.082_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2020.09.082_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.radonc.2019.11.010","article-title":"Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: a systematic review and meta-analysis of multidisciplinary approaches","volume":"144","author":"Singh","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib43","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"199","author":"Chen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 4","key":"10.1016\/j.wneu.2020.09.082_bib44","doi-asserted-by":"crossref","first-page":"iv465","DOI":"10.1093\/annonc\/mdu349.103","article-title":"1324P - Tumor-Infiltrating lymphocytes (Tils) and Pd-L1 expression in non-small cell lung cancer brain metastases (Bm) and matched primary tumors (Pt)","volume":"25","author":"Berghoff","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2020.09.082_bib45","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites","volume":"21","author":"Kluger","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875020320908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875020320908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:53:20Z","timestamp":1761814400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875020320908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":45,"alternative-id":["S1878875020320908"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2020.09.082","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2020.09.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}